Technical and clinical experience with Protein A Immunoadsorption columns

Belák, M; Borberg, H.; Jiménez, Carlos; Oette, K.

doi:10.1016/0955-3886(94)90174-0

Cited by 42 publications

(37 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…IA is a specific technique for removing isoagglutinins and is part of the ABO-I desensitisation protocol in most European centers at present [44]. IA can faster to remove DSA than DFPP [45], and compared to plasmapheresis, IA allows not only a more specific but also a more effective clearance of circulating immunoglobulins without the side effects associated with the substitution of FFP or albumin [46,47]. However, the higher costs associated with the use of IA indicates its use in high-risk populations (i.e., hyperimmune or ABO-I patients, pretransplantcross-match positivity, AAMR) [38].…”

Section: Discussionmentioning

confidence: 99%

Plasmapheresis Therapy in Kidney Transplant Rejection

et al. 2018

View full text Add to dashboard Cite

Kidney transplantation (KT) is considered an optimal treatment strategy for end-stage renal disease. But human leukocyte antigen-sensitized, ABO-incompatible and antibody-mediated rejection might be the alarming hurdles in KT. Therapeutic plasma exchange is the mainstay of the antibody reduction therapy for reducing autoantibody more effectively. Even in the treatment for highly sensitized patients, it has played an indispensable role. However, clinicians should tailor therapies to individual patient’s needs and multimodal treatment will bring better outcomes. Early diagnosis and precise treatment would reduce morbidity, mortality, and economic costs.

show abstract

Section: Discussionmentioning

confidence: 99%

Plasmapheresis Therapy in Kidney Transplant Rejection

et al. 2018

View full text Add to dashboard Cite

show abstract

“…(59) Similar columns for removal of donor-specific alloantibody would require large amounts of donor HLA antigens, which is technically and financially unfeasible at the current time. In general, IA can remove up to 87% of plasma IgG and over 50% of the IgA and IgM per treatment, as well as Ig-bound complement proteins (54, 57, 58, 60). IA has several advantages over TPE: it does not remove clotting factors, requires no substitution of plasma, antibodies against previously encountered antigens are somewhat preserved, and has the potential of reusable adsorption systems (58, 60, 61).…”

Section: Emerging Targets For Clinical Interventionmentioning

confidence: 99%

“…In general, IA can remove up to 87% of plasma IgG and over 50% of the IgA and IgM per treatment, as well as Ig-bound complement proteins (54, 57, 58, 60). IA has several advantages over TPE: it does not remove clotting factors, requires no substitution of plasma, antibodies against previously encountered antigens are somewhat preserved, and has the potential of reusable adsorption systems (58, 60, 61). Similar to TPE, however, IA does not alter IgG synthesis or redistribution from tissue compartments, and additional B and plasma cell depleting therapies are needed for sustained DSA reduction (58).…”

Section: Emerging Targets For Clinical Interventionmentioning

confidence: 99%

“…In a case series, 2 patients with evidence of AMR, DSA could be eliminated after treatment with IA and rituximab (52). Reported adverse effects of AI include high cost, citrate toxicity, reduced antibodies against pneumococcus and haemophilous polysaccharide antigens, and anaphylaxis with concurrent ACEI use (57, 58, 60). Additional studies directly comparing TPE and IA are needed.…”

Section: Emerging Targets For Clinical Interventionmentioning

confidence: 99%

See 1 more Smart Citation

Rational clinical trial design for antibody mediated renal allograft injury

Sandal

Zand

2015

Front Biosci

View full text Add to dashboard Cite

Antibody mediated renal allograft rejection is a significant cause of acute and chronic graft loss. Recent work has revealed that AMR is a complex processes, involving B and plasma cells, donor-specific antibodies, complement, vascular endothelial cells, NK cells, Fc receptors, cytokines and chemokines. These insights have led to the development of numerous new therapies, and adaptation of others originally developed for treatment of hemetologic malignancies, autoimmune and complement mediated conditions. Here we review emerging insights into the pathophysiology of AMR as well as current and emerging therapies for both acute and chronic AMR. Finally, we discuss rational clinical trial design in light of antibody and B cell immunobiology, as well as appropriate efficacy metrics to identify robust protocols and therapeutic agents.

show abstract

“…9,10) We investigated the in vivo pharmacokinetics and disposition property of ctDNA in a previous study, to evaluate its safety of use as an immunoadsorptive carrier material for therapy. 11,12) Although it was proved ctDNA can be effectively eliminated in plasma and would not accumulate in the body of animal, in the practical application, the patients who have leprosy or systemic lupus erythematosus (SLE) may undergo synergistic cure with other drugs together with ctDNA, or other kind of drugs were simultaneously or successively used against other diseases and medical conditions.…”

Section: Introductionmentioning

confidence: 99%

Inhibitory Effects of Calf Thymus DNA on Metabolism Activity of CYP450 Enzyme in Human Liver Microsomes

Yang¹,

Qiu²,

Zhang³

et al. 2014

Drug Metabolism and Pharmacokinetics

View full text Add to dashboard Cite

The present study investigated the effect of calf thymus DNA (ctDNA) on human hepatic cytochrome P450s (CYP450s) in vitro. Specific substrate probes for each isoform, CYP1A2, 2C9, 2C19, 2D6 and 3A4, were incubated using pooled human liver microsomes with or without ctDNA, and liquid chromatography coupled tandem mass spectrometry (LC-MS/MS) method was developed for the analysis of probe metabolites. Enzyme kinetics parameters Ki and IC50 values were estimated to determine the types and strength of inhibition. ctDNA could specifically inhibit the metabolism of CYP2C9 probe substrates, with the IC50 = 0.9955 µg/ml, while it was not able to inhibit CYP1A2, CYP2C19, CYP2D6 or CYP3A4 (IC50 > 100 µg/ml). The results showed that ctDNA was a potent inhibitor of CYP2C9 enzyme, and has the metabolic interaction potential with the model drugs which are metabolism substrates of CYP2C9. The inhibition mechanism study suggested ctDNA may inhibit CYP2C9 by decreasing the activity of CYP450 reductase. These findings indicated that when the medical agents catalyzed mainly by CYP2C9 were co-administered in vivo with adsorptive material in vitro, the potential inhibitory effect of ctDNA on enzyme activity and the following metabolism character changes of the former should be highly focused on.

show abstract

Technical and clinical experience with Protein A Immunoadsorption columns

Cited by 42 publications

References 2 publications

Plasmapheresis Therapy in Kidney Transplant Rejection

Plasmapheresis Therapy in Kidney Transplant Rejection

Rational clinical trial design for antibody mediated renal allograft injury

Inhibitory Effects of Calf Thymus DNA on Metabolism Activity of CYP450 Enzyme in Human Liver Microsomes

Contact Info

Product

Resources

About